Polymerase chain reaction-triggered preemptive or deferred therapy to control cytomegalovirus-associated morbidity and costs in renal transplant patients.
Brennan
D C
DC
Washington University School of Medicine, St. Louis, Missouri, USA.
Garlock
K A
KA
Lippmann
B J
BJ
Buller
R S
RS
Gaudreault-Keener
M
M
Lowell
J A
JA
Miller
S B
SB
Shenoy
S
S
Howard
T K
TK
Storch
G A
GA
D000961:Antilymphocyte Serum / Q000627:therapeutic use; D000998:Antiviral Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001379:Azathioprine / Q000627:therapeutic use; D003365:Costs and Cost Analysis; D016572:Cyclosporine / Q000627:therapeutic use; D003587:Cytomegalovirus / Q000302:isolation & purification*; D003586:Cytomegalovirus Infections / Q000188:drug therapy* / Q000191:economics / Q000517:prevention & control*; D005500:Follow-Up Studies; D015774:Ganciclovir / Q000009:adverse effects / Q000627:therapeutic use*; D006084:Graft Rejection / Q000453:epidemiology; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000191:economics; D009017:Morbidity; D016133:Polymerase Chain Reaction / Q000379:methods*; D011183:Postoperative Complications; D011241:Prednisone / Q000627:therapeutic use; D012680:Sensitivity and Specificity; D014481:United States; D014766:Viremia / Q000175:diagnosis / Q000191:economics / Q000453:epidemiology
D000961:Antilymphocyte Serum; D000998:Antiviral Agents; D007166:Immunosuppressive Agents; D016572:Cyclosporine; D001379:Azathioprine; D015774:Ganciclovir; D011241:Prednisone